Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003

Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 June 1, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company‚Äôs immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the …